Yao Wang

Yao Wang

Auto-generated profile, based on publicly available information

Yao Wang

Department of Cardiology The First Affiliated Hospital of Nanjing Medical University Nanjing China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YWYao Wang
Yao Wang
KGKai Gu
Kai Gu
ZQZhiyong Qian
Zhiyong Qian
XHXiaofeng Hou
Xiaofeng Hou
XCXing Chen
Xing Chen
JZJiangang Zou
Jiangang Zou

3 January 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
XCXing Chen
Xing Chen
ZQZhiyong Qian
Zhiyong Qian
FZFengwei Zou
Fengwei Zou
YWYao Wang
Yao Wang
XZXinwei Zhang
Xinwei Zhang
JZJiangang Zou
Jiangang Zou

12 October 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
JHJin Huang
Jin Huang
JZJian-Lin Zhang
Jian-Lin Zhang
LALin Ang
Lin Ang
MLMingcong Li
Mingcong Li
MZMin Zhao
Min Zhao
QWQiang Wu
Qiang Wu
Background: High relapse rates remain a clinical challenge in the management of breast cancer (BC), with distant recurrence being a major driver of patient deterioration. To optimize the surveillance regimen for distant recurrence after neoadjuvant chemotherapy (NAC), we conducted a comprehensive analysis using bioinformatics and machine learning approaches.Materials and methods: Microarray data were retrieved from the GEO database, and differential expression analysis was performed with the R package ‘Limma’. We used the Metascape tool for enrichment analyses, and ‘WGCNA’ was utilized to establish co-expression networks, selecting the soft threshold power with the ‘pickSoftThreshold’ algorithm. We integrated ten machine learning algorithms and 101 algorithm combinations to identify key genes associated with distant recurrence in BC. Unsupervised clustering was performed with the R package ‘ConsensusCluster Plus’. To further screen the key gene signature of residual cancer burden (RCB), multiple knockdown studies were analyzed with the Genetic Perturbation Similarity Analysis (GPSA) database. Single-cell RNA sequencing (scRNA-seq) analysis was conducted through the Tumour Immune Single-cell Hub (TISCH) database, and the XSum algorithm was used to screen candidate small molecule drugs based on the Connectivity Map (CMAP) database. Molecular docking processes were conducted using Schrodinger software. GMT files containing gene sets associated with metabolism and senescence were obtained from GSEA MutSigDB database. The GSVA score for each gene set across diverse samples was computed using the ssGSEA function implemented in the GSVA package.Results: Our analysis, which combined Limma, WGCNA, and machine learning approaches, identified 16 RCB-relevant gene signatures influencing distant recurrence-free survival (DRFS) in BC patients following NAC. We then screened GATA3 as the key gene signature of high RCB index using GPSA analysis. A novel molecular subtyping scheme was developed to divide patients into two clusters (C1 and C2) with different distant recurrence risks. This molecular subtyping scheme was found to be closely associated with tumor metabolism and cellular senescence. Patients in cluster C2 had a poorer DRFS than those in cluster C1 (HR: 4.04; 95% CI: 2.60–6.29; log-rank test p < 0.0001). High GATA3 expression, high levels of resting mast cell infiltration, and a high proportion of estrogen receptor (ER)-positive patients contributed to better DRFS in cluster C1. We established a nomogram based on the N stage, RCB class, and molecular subtyping. The ROC curve for 5-year DRFS showed excellent predictive value (AUC=0.91, 95% CI: 0.95–0.86), with a C-index of 0.85 (95% CI: 0.81–0.90). Entinostat was identified as a potential small molecule compound to reverse high RCB after NAC. We also provided a comprehensive review of the EDCs exposures that potentially impact the effectiveness of NAC among BC patients.Conclusion: This study established a molecular classification scheme associated with tumor metabolism and cancer cell senescence to predict RCB and DRFS in BC patients after NAC. Furthermore, GATA3 was identified and validated as a key gene associated with BC recurrence.

3 May 2023 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
YHYing He
Ying He
ZTZhijie Tang
Zhijie Tang
GSGuozhen Sun
Guozhen Sun
CCCheng Cai
Cheng Cai
YWYao Wang
Yao Wang
ZBZhiPeng Bao
ZhiPeng Bao
Background: Radiofrequency catheter ablation (RFCA) for patients with atrial fibrillation (AF) can generate considerable physical and psychological discomfort under conscious sedation. App-based mindfulness meditation combined with an electroencephalography (EEG)-based brain-computer interface (BCI) shows promise as effective and accessible adjuncts in medical practice. Objective: This study aimed to investigate the effectiveness of a BCI-based mindfulness meditation app in improving the experience of patients with AF during RFCA. Methods: This single-center pilot randomized controlled trial involved 84 eligible patients with AF scheduled for RFCA, who were randomized 1:1 to the intervention and control groups. Both groups received a standardized RFCA procedure and a conscious sedative regimen. Patients in the control group were administered conventional care, while those in the intervention group received BCI-based app–delivered mindfulness meditation from a research nurse. The primary outcomes were the changes in the numeric rating scale, State Anxiety Inventory, and Brief Fatigue Inventory scores. Secondary outcomes were the differences in hemodynamic parameters (heart rate, blood pressure, and peripheral oxygen saturation), adverse events, patient-reported pain, and the doses of sedative drugs used in ablation. Results: BCI-based app–delivered mindfulness meditation, compared to conventional care, resulted in a significantly lower mean numeric rating scale (mean 4.6, SD 1.7 [app-based mindfulness meditation] vs mean 5.7, SD 2.1 [conventional care]; P=.008), State Anxiety Inventory (mean 36.7, SD 5.5 vs mean 42.3, SD 7.2; P<.001), and Brief Fatigue Inventory (mean 3.4, SD 2.3 vs mean 4.7, SD 2.2; P=.01) scores. No significant differences were observed in hemodynamic parameters or the amounts of parecoxib and dexmedetomidine used in RFCA between the 2 groups. The intervention group exhibited a significant decrease in fentanyl use compared to the control group, with a mean dose of 3.96 (SD 1.37) mcg/kg versus 4.85 (SD 1.25) mcg/kg in the control group (P=.003).The incidence of adverse events was lower in the intervention group (5/40) than in the control group (10/40), though this difference was not significant (P=.15). Conclusions: BCI-based app–delivered mindfulness meditation effectively relieved physical and psychological discomfort and may reduce the doses of sedative medication used in RFCA for patients with AF. Trial Registration: ClinicalTrials.gov NCT05306015; https://clinicaltrials.gov/ct2/show/NCT05306015

17 March 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
YZYangchun Zhou
Yangchun Zhou
YWYao Wang
Yao Wang
SWShou-Lin Wang
Shou-Lin Wang
LSLizong Shen
Lizong Shen

23 March 2022 in International Journal of Cardiology
Verified
Journal Article
Closed access
ZQZhiyong Qian
Zhiyong Qian
CQChaotong Qin
Chaotong Qin
FZFengwei Zou
Fengwei Zou
SXSiyuan Xue
Siyuan Xue
YWYao Wang
Yao Wang
JZJiangang Zou
Jiangang Zou